DrugCentral 2023 ๐
2022 Update-Veterinary Drugs & Uses
Search
Structure ๐
Similarity ๐
Smart API
Redial
About
Download
L1000
FAQ
DrugCentral 2023 ๐
2022 Update-Veterinary Drugs & Uses
Search
Structure ๐
Similarity ๐
Smart API
Redial
About
Download
L1000
FAQ
Scroll
All
FDA-approved
EMA-approved
PMDA-approved
Target Card Uniprot Example:
P23975
estramustine phosphate ๐ถ
Veterinary Use |
Indications/Contra
| FAERs-F
| FAERs-M
| Orange Bk
| BioActivity |
Stem definition
Drug id
CAS RN
antineoplastic, alkylating agents, (beta-chloroethyl)amine derivatives
1066
4891-15-0
Description:
Molecule
Description
Molfile
Inchi
Smiles
Synonyms:
emcyt
estramustine phosphate
estramustine phosphate sodium
Molecular weight: 520.38
Formula: C23H32Cl2NO6P
CLOGP: 3.27
LIPINSKI: 1
HAC: 7
HDO: 2
TPSA: 96.30
ALOGS: -6.05
ROTB: 8
Status: OFP
Legend:
OFP - off patent
OFM - off market
ONP - on patent
Drug dosage:
None
ADMET properties:
Show
10
25
50
100
entries
Search:
Property
Value
Reference
BA (Bioavailability)
43.70 %
Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
t_half (Half-life)
2.40 hours
Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)
16.47 ยตM/kg/day
Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
S (Water solubility)
10 mg/mL
Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)
1
Bocci G, Oprea TI, Benet LZ
CL (Clearance)
0.94 mL/min/kg
Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)
0.50 %
Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)
0.12 L/kg
Lombardo F, Berellini G, Obach RS
Showing 1 to 8 of 8 entries
Previous
1
Next
Approvals:
Show
10
25
50
100
entries
Search:
Date
Agency
Company
Orphan
Dec. 24, 1981
FDA
PHARMACIA AND UPJOHN
Showing 1 to 1 of 1 entries
Previous
1
Next
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
Show
10
25
50
100
entries
Search:
MedDRA adverse event term
Likelihood ratio
Likelihood ratio threshold
Patients taking drug having adverse event
Patients taking drug not having adverse event
Patients not taking drug having adverse event
Patients not taking drug not having adverse event
Osteonecrosis of jaw
79.08
31.55
23
526
17866
34938516
Showing 1 to 1 of 1 entries
Previous
1
Next
FDA Adverse Event Reporting System (Geriatric)
Show
10
25
50
100
entries
Search:
MedDRA adverse event term
Likelihood ratio
Likelihood ratio threshold
Patients taking drug having adverse event
Patients taking drug not having adverse event
Patients not taking drug having adverse event
Patients not taking drug not having adverse event
Osteonecrosis of jaw
74.10
37.53
20
327
43206
79700835
Showing 1 to 1 of 1 entries
Previous
1
Next
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
Show
10
25
50
100
entries
Search:
Source
Code
Description
MeSH PA
D000477
Alkylating Agents
MeSH PA
D000970
Antineoplastic Agents
MeSH PA
D018906
Antineoplastic Agents, Alkylating
MeSH PA
D018931
Antineoplastic Agents, Hormonal
MeSH PA
D009676
Noxae
Showing 1 to 5 of 5 entries
Previous
1
Next
Drug Use
| Suggest Off label Use Form|
|View source of the data|
None
๐ถ Veterinary Drug Use
None
๐ถ Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
Show
10
25
50
100
entries
Search:
Dissociation level
Dissociation constant
Type (acidic/basic)
pKa1
1.98
acidic
pKa2
7.03
acidic
Showing 1 to 2 of 2 entries
Previous
1
Next
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
Show
10
25
50
100
entries
Search:
Target
Class
Pharos
UniProt
Action
Type
Activity value
(-log[M])
Mechanism
action
Bioact source
MoA source
Estrogen receptor beta
Nuclear hormone receptor
Q92731
ESR2_HUMAN
MODULATOR
CHEMBL
CHEMBL
Tyrosine-protein phosphatase non-receptor type 1
Enzyme
P18031
PTN1_HUMAN
IC50
4.20
CHEMBL
Tyrosine-protein phosphatase non-receptor type 11
Enzyme
Q06124
PTN11_HUMAN
Kd
5.08
CHEMBL
Protein-tyrosine phosphatase 1C
Enzyme
P29350
PTN6_HUMAN
IC50
4.39
CHEMBL
Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2
Enzyme
O15357
SHIP2_HUMAN
IC50
4.45
CHEMBL
Showing 1 to 5 of 5 entries
Previous
1
Next
External reference:
Show
10
25
50
100
entries
Search:
ID
Source
002668
NDDF
007183
NDDF
105556
RXNORM
108769008
SNOMEDCT_US
1227300-83-5
SECONDARY_CAS_RN
259329
PUBCHEM_CID
326745006
SNOMEDCT_US
4017795
VANDF
4687
MMSL
691
MMSL
Showing 1 to 10 of 18 entries
Previous
1
2
Next
Pharmaceutical products:
Show
10
25
50
100
entries
Search:
Product
Category
Ingredients
NDC
Form
Quantity
Route
Marketing
Label
Emcyt
HUMAN PRESCRIPTION DRUG LABEL
1
0013-0132
CAPSULE
140 mg
ORAL
NDA
18 sections
Emcyt
HUMAN PRESCRIPTION DRUG LABEL
1
0013-0132
CAPSULE
140 mg
ORAL
NDA
18 sections
Showing 1 to 2 of 2 entries
Previous
1
Next
Search
Structure ๐
Similarity ๐
Smart API
Redial
About
Download
L1000
FAQ
estramustine phosphate